Myriad Genetics Company Profile (NASDAQ:MYGN)

Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."

Myriad Genetics, Inc. (NASDAQ:MYGN) announced its quarterly earnings results on Tuesday, August, 8th. The company reported $0.30 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.26 by $0.04. The company earned $200.50 million during the quarter, compared to the consensus estimate of $193.71 million. Myriad Genetics had a net margin of 2.83% and a return on equity of 9.67%. The firm's quarterly revenue was up 7.5% compared to the same quarter last year. During the same quarter last year, the firm earned $0.36 earnings per share. View Myriad Genetics' Earnings History.

Myriad Genetics is scheduled to release their next quarterly earnings announcement on Monday, October, 30th 2017. View Earnings Estimates for Myriad Genetics.

Myriad Genetics issued an update on its FY18 earnings guidance on Tuesday, August, 8th. The company provided EPS guidance of $1.00-1.05 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.08. The company issued revenue guidance of $750-770 million, compared to the consensus revenue estimate of $789.30 million.Myriad Genetics also updated its Q1 guidance to $0.19-0.21 EPS.

10 brokerages have issued 12-month price objectives for Myriad Genetics' stock. Their predictions range from $15.00 to $40.00. On average, they anticipate Myriad Genetics' stock price to reach $24.67 in the next year. View Analyst Ratings for Myriad Genetics.

Here are some recent quotes from research analysts about Myriad Genetics stock:

• 1. According to Zacks Investment Research, "Over the last three months, Myriad Genetics has been trading above the broader industry. While we await the company to release its first quarter fiscal 2018 results, we expect it to deliver another quarter of strong topline on the back of solid growth in EndoPredict and GeneSight testing revenues. Also, the company witnessed a third consecutive quarter of rise in hereditary cancer volumes. We are currently upbeat about the receipt of positive coverage decision for EndoPredict tests from Palmetto GBA. Also, it received provincial reimbursement in Quebec for the same.  Recently, the company introduced riskScore under its myRisk Hereditary Cancer testing portfolio.  On the flip side, a dull operating margin scenario owing to a rise in operating expenses is disappointing. Currency fluctuations and stiff competition are other major headwinds for the company." (10/17/2017)
• 2. Cowen and Company analysts commented, "The FDA approved Tesaro's niraprarib (Zejula) yesterday. This approval was not limited to mutational status, and therefore does not require MYGN's myChoice HRD test. This outcome is consistent with our thoughts since last June, and as a result has limited impact to our MYGN financial forecast." (3/28/2017)

Some companies that are related to Myriad Genetics include athenahealth (ATHN), Bio-Techne Corp (TECH), HealthSouth Corporation (HLS), Juno Therapeutics (JUNO), Medidata Solutions (MDSO), PAREXEL International Corporation (PRXL), Masimo Corporation (MASI), ACADIA Pharmaceuticals (ACAD), Taro Pharmaceutical Industries (TARO), VWR Corporation (VWR), Valeant Pharmaceuticals International (VRX), Akorn (AKRX), Mednax (MD), Cantel Medical Corp. (CMD), Integra LifeSciences Holdings Corporation (IART), DexCom (DXCM), Acadia Healthcare Company (ACHC) and FibroGen (FGEN).

Myriad Genetics' management team includes the folowing people:

• John T. Henderson M.D., Independent Chairman of the Board
• Mark C. Capone, President, Chief Executive Officer, Director
• Walter M. Gilbert Ph.D., Independent Vice Chairman of the Board
• R. Bryan Riggsbee CPA, Chief Financial Officer, Treasurer
• Virginia C. Drosos, President of Assurex Health, Inc.
• Alexander Ford, President of Myriad Genetic Laboratories, Inc.
• Ralph L. McDade Ph.D., President of Myriad RBM, Inc
• Bernard F. Tobin, President of Crescendo Bioscience, Inc
• Richard M. Marsh Esq., Executive Vice President, General Counsel, Secretary
• Gary A. King, Executive Vice President - International Operations

Myriad Genetics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Eqis Capital Management Inc. (0.04%). Company insiders that own Myriad Genetics stock include Alexander Ford, Gary A King, Heinrich Dreismann, Jerry S Lanchbury, John T Henderson, Mark Christopher Capone, Ralph L Mcdade, Richard M Marsh, S Louise Phanstiel and Walter Phd Gilbert. View Institutional Ownership Trends for Myriad Genetics.

Myriad Genetics' stock was sold by a variety of institutional investors in the last quarter, including Eqis Capital Management Inc.. View Insider Buying and Selling for Myriad Genetics.

Shares of Myriad Genetics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Myriad Genetics stock can currently be purchased for approximately $34.39.